Spots Global Cancer Trial Database for fedratinib
Every month we try and update this database with for fedratinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03755518 | Primary Myelofi... Post-Polycythem... Myelofibrosis Post-essential ... | FEDRATINIB | 18 Years - | Celgene | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| Real World Evidence of Fedratinib Effectiveness in MF | NCT05883904 | Primary Myelofi... Post-polycythem... Post-essential ... | Fedratinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis | NCT06073847 | Primary Myelofi... Post-polycythem... Post-essential ... | Fedratinib | 19 Years - | Bristol-Myers Squibb | |
| Real World Evidence of Fedratinib Effectiveness in MF | NCT05883904 | Primary Myelofi... Post-polycythem... Post-essential ... | Fedratinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | NCT04955938 | IDH Mutation IDH1 Mutation IDH2 Gene Mutat... Blood Cancer Myeloproliferat... | Ivosidenib Enasidenib Fedratinib | 18 Years - | University of Chicago | |
| Real World Evidence of Fedratinib Effectiveness in MF | NCT05883904 | Primary Myelofi... Post-polycythem... Post-essential ... | Fedratinib | 18 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | NCT04817007 | Myelofibrosis | BMS-986158 Ruxolitinib Fedratinib | 18 Years - | Bristol-Myers Squibb | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
